Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

Women Respond to FDA Ruling on Avastin

Women with metastatic breast cancer share how they feel about FDA’s decision to rescind approval of bevacizumab (Avastin) as a treatment for metastatic breast cancer.

FDA Approves Bone Medicine for Use in Bone Metastasis

The Food and Drug Administration (FDA) has approved denosumab to help prevent bone damage in people with cancer that has spread to the bone tissue.

LBBC Medical Advisors React to Avastin Decision

Members of Living Beyond Breast Cancer's Medical Advisory Board react to the FDA decision to withdraw approval of Avastin as a treatment for metastatic breast cancer.

Living Beyond Breast Cancer Statement on FDA’s Decision to Remove Approval of Avastin for Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) yesterday announced that it plans to begin the process necessary to withdraw approval of Avastin (bevacizumab) as a treatment for metastatic breast cancer. Living Beyond Breast Cancer (LBBC) encourages insurance carriers and the federal government to continue reimbursing payment for Avastin for women currently taking it who are responding to it. Additionally, we strongly encourage the manufacturer to continue its program to assist women in need who are taking Avastin and are responding.

FDA Rules Against Avastin

FDA's announcement that it plans to withdraw approval of Avastin in metastatic breast cancer begins a review process that could last several months. Learn about the timeline for a decision, the impact on access and insurance coverage, and how to submit public comments to FDA.

CORRECTION: Can depression influence breast cancer survival?

NEW YORK (Reuters Health) - A diagnosis of breast cancer will inevitably sink a woman's mood, but those whose spirits lift over time appear to survive longer, a new study suggests.

Popular new breast cancer treatment lacks data

NEW YORK (Reuters Health) - A new radiation treatment for breast cancer is becoming increasingly popular despite lack of good evidence, at least among well-insured Medicare patients, U.S. researchers say,.

Amgen drug delays bone problems longer than Zometa

NEW YORK (Reuters) - Amgen Inc's new osteoporosis drug denosumab delayed fractures and other bone problems in patients with advanced breast cancer five months longer than Novartis AG's Zometa, according to data from a large clinical trial.

Two Roche drugs plus chemo destroy breast tumors

LOS ANGELES (Reuters) - Combining experimental antibody drug pertuzumab with Herceptin, an antibody first approved in 1998, and chemotherapy shrank tumors in nearly half of newly diagnosed breast cancer patients treated in a clinical trial.

Zometa fails to help breast cancer survival: study

NEW YORK (Reuters) - The Novartis osteoporosis drug Zometa failed to improve disease free survival of early breast cancer patients in a large clinical trial, but some benefit was observed in older patients who took the medicine, researchers said.

Close
close